X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of hospitalized patients for COVID-19 infection.
Lead Product(s): Azeliragon
Therapeutic Area: Infections and Infectious Diseases Product Name: TTP488
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michigan Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of refractory to first-line treatment of metastatic pancreatic cancer.
Lead Product(s): Azeliragon,Dexamethasone
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of patients newly diagnosed unmethylated glioblastoma.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lenox Hill Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of RAGE with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment.
Lead Product(s): Azeliragon,Dexamethasone
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Under the agreement, Cantex gets exclusive worldwide license for intellectual property related to the potential use of TTP488 (azeliragon), a small molecule RAGE inhibitor, to treat, prevent or alleviate cancer treatment-related cognitive decline.
Lead Product(s): Azeliragon,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Neurology Product Name: TTP488
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Georgetown University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2023
Details:
Under the agreement, Cantex obtained an exclusive worldwide license for intellectual property related to the potential use of TTP-488 (azeliragon) to treat, prevent or alleviate cancer-treatment related cognitive decline.
Lead Product(s): Azeliragon
Therapeutic Area: Psychiatry/Psychology Product Name: TTP-488
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Georgetown University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2023
Details:
TTP488 (azeliragon) is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). By preventing interaction of RAGE with these ligands, azeliragon may inhibit glioblastoma and overcome its resistance to effective treatment.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of patients hospitalized for COVID-19.
Lead Product(s): Azeliragon
Therapeutic Area: Infections and Infectious Diseases Product Name: TTP488
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michigan Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). A broad range of evidence suggests that RAGE ligand interactions play a critical role in cancer and in inflammatory diseases.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Miami Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
TTP488 (Azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). A broad range of evidence suggests that RAGE ligand interactions play a critical role in cancer and in inflammatory diseases.
Lead Product(s): Azeliragon,Temozolomide
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
